Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Changming Xia

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Advances in Therapy|January 10, 2023
Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global RegistryRebecca Gall, Neal Jain, Weily Soong, et al.
Nanophotonics (Berlin, Germany)|December 5, 2024
A novel multicore Er/Yb co-doped microstructured optical fiber amplifier with peanut-shaped air holes claddingYifan Zhang, Yifei Zhao, Ziwei Fang, et al.
Expert Review of Gastroenterology & Hepatology|February 5, 2025
Dupilumab is efficacious for eosinophilic esophagitis irrespective of prior swallowed budesonide or fluticasone, or prior treatments used alongside swallowed topical corticosteroids: results from the phase 3, randomized, placebo-controlled, LIBERTY EoE TREET trialAlbert J Bredenoord, Evan S Dellon, Christoph Schlag, et al.
Advances in Therapy|September 27, 2025
Peak Nasal Inspiratory Flow and the Association with Nasal Obstruction in Patients with Severe CRSwNP from the SINUS-24/-52 StudiesMartin Desrosiers, Scott Nash, Andrew Lane, et al.
The American Journal of Gastroenterology|July 10, 2026
Dupilumab Improves Endoscopic Features in Children Aged 1-11 Years With Eosinophilic Esophagitis: EoE KIDS Study ResultsShauna Schroeder, Mirna Chehade, Calies Menard-Katcher, et al.
The Journal of Allergy and Clinical Immunology|June 30, 2026
Dupilumab outcomes in pediatric asthma by early eosinophil status: post hoc analysis of VOYAGE/EXCURSIONSharon Dell, Theresa W Guilbert, Antoine Deschildre, et al.
American Journal of Respiratory and Critical Care Medicine|May 19, 2026
Dupilumab in COPD: A Pooled Analysis of Emergency Department Visits, Hospital Admissions, and Systemic Corticosteroid UseSurya P Bhatt, Fernando J Martinez, Imran Satia, et al.
American Journal of Otolaryngology|January 31, 2025
Baseline disease characteristics by surgery history among patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in the global AROMA registryShigeharu Fujieda, Jayant M Pinto, David W Jang, et al.
Advances in Therapy|April 30, 2026
Coexisting Type 2 Inflammatory Conditions in Patients with Asthma Treated with Dupilumab: the RAPID RegistryAnju T Peters, Andréanne Côté, Xavier Muñoz, et al.
Journal of Asthma and Allergy|June 30, 2025
Comparing Baseline Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps with and without Asthma in the AROMA RegistryAnju T Peters, Enrico Heffler, Kathleen M Buchheit, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Advances in Therapy|January 10, 2023
Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global RegistryRebecca Gall, Neal Jain, Weily Soong, et al.
Nanophotonics (Berlin, Germany)|December 5, 2024
A novel multicore Er/Yb co-doped microstructured optical fiber amplifier with peanut-shaped air holes claddingYifan Zhang, Yifei Zhao, Ziwei Fang, et al.
Expert Review of Gastroenterology & Hepatology|February 5, 2025
Dupilumab is efficacious for eosinophilic esophagitis irrespective of prior swallowed budesonide or fluticasone, or prior treatments used alongside swallowed topical corticosteroids: results from the phase 3, randomized, placebo-controlled, LIBERTY EoE TREET trialAlbert J Bredenoord, Evan S Dellon, Christoph Schlag, et al.
Advances in Therapy|September 27, 2025
Peak Nasal Inspiratory Flow and the Association with Nasal Obstruction in Patients with Severe CRSwNP from the SINUS-24/-52 StudiesMartin Desrosiers, Scott Nash, Andrew Lane, et al.
The American Journal of Gastroenterology|July 10, 2026
Dupilumab Improves Endoscopic Features in Children Aged 1-11 Years With Eosinophilic Esophagitis: EoE KIDS Study ResultsShauna Schroeder, Mirna Chehade, Calies Menard-Katcher, et al.
The Journal of Allergy and Clinical Immunology|June 30, 2026
Dupilumab outcomes in pediatric asthma by early eosinophil status: post hoc analysis of VOYAGE/EXCURSIONSharon Dell, Theresa W Guilbert, Antoine Deschildre, et al.
American Journal of Respiratory and Critical Care Medicine|May 19, 2026
Dupilumab in COPD: A Pooled Analysis of Emergency Department Visits, Hospital Admissions, and Systemic Corticosteroid UseSurya P Bhatt, Fernando J Martinez, Imran Satia, et al.
American Journal of Otolaryngology|January 31, 2025
Baseline disease characteristics by surgery history among patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in the global AROMA registryShigeharu Fujieda, Jayant M Pinto, David W Jang, et al.
Advances in Therapy|April 30, 2026
Coexisting Type 2 Inflammatory Conditions in Patients with Asthma Treated with Dupilumab: the RAPID RegistryAnju T Peters, Andréanne Côté, Xavier Muñoz, et al.
Journal of Asthma and Allergy|June 30, 2025
Comparing Baseline Characteristics of Patients with Chronic Rhinosinusitis with Nasal Polyps with and without Asthma in the AROMA RegistryAnju T Peters, Enrico Heffler, Kathleen M Buchheit, et al.
Pageof 4